Jazz Pharmaceuticals continues to grapple with sustaining revenues from its oxybate franchise, notably Xyrem and Xywav, amid rising competition from authorized generics and branded alternatives. The company’s recent filings reflect heightened regulatory scrutiny, pricing pressures, and patent litigation risks that could materially affect its leading narcolepsy treatments. While Jazz has bolstered its pipeline via acquisitions like Chimerix, ongoing integration challenges and external market constraints create uncertainty for near-term growth prospects.